Literature DB >> 1744579

Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41.

C F Ebenbichler1, N M Thielens, R Vornhagen, P Marschang, G J Arlaud, M P Dierich.   

Abstract

Human immunodeficiency virus type 1 (HIV-1), in contrast to animal retroviruses such as murine leukemia virus, is not lysed by human complement. Nevertheless, HIV-1 activates complement via the classical pathway independent of antibody, and C3b deposition facilitates infection of complement receptor-bearing cells. Using gel exclusion chromatography on Sephacryl S-1000, purified virions were found to bind 125I-labeled C1q, but not 125I-labeled dimeric proenzyme C1s. Virions activated the C1 complex, reconstituted from C1q, proenzyme C1r, and 125I-labeled proenzyme C1s, to an extent comparable with that obtained with immunoglobulin G-ovalbumin immune complexes. To determine the activating viral component, recombinant viral proteins were used: in the solid phase, soluble gp41 (sgp41) (the outer membrane part of gp41, residues 539-684 of gp160) bound C1q, but not dimeric proenzyme C1s, while gp120 was ineffective. In the fluid phase, sgp41 activated the C1 complex in a dose- and time-dependent manner, more efficiently than aggregated Ig, but less efficiently than immune complexes. To localize the C1 activating site(s) in gp41, synthetic peptides (15-residue oligomers spanning amino acids 531-695 of gp160) were used. Peptides covering positions 591-605 and 601-620 and, to a lesser extent, positions 561-575, had both the ability to bind C1q and to induce C3 deposition. These data provide the first experimental evidence of a direct interaction between the C1 complex and HIV-1, and indicate that C1 binding and activation are mediated by specific sites in gp41.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744579      PMCID: PMC2119058          DOI: 10.1084/jem.174.6.1417

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  55 in total

1.  Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

Authors:  J W Gnann; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

2.  HIV and HIV-infected cells differentially activate the human complement system independent of antibody.

Authors:  B M Sölder; T F Schulz; P Hengster; J Löwer; C Larcher; G Bitterlich; R Kurth; H Wachter; M P Dierich
Journal:  Immunol Lett       Date:  1989-08       Impact factor: 3.685

3.  Binding and activation of the first component of human complement by the lipid A region of lipopolysaccharides.

Authors:  N R Cooper; D C Morrison
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

4.  Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.

Authors:  C Mold; B M Bradt; G R Nemerow; N R Cooper
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

5.  Reversible binding of Pi by beef heart mitochondrial adenosine triphosphatase.

Authors:  H S Penefsky
Journal:  J Biol Chem       Date:  1977-05-10       Impact factor: 5.157

6.  The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum.

Authors:  B Banapour; J Sernatinger; J A Levy
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

7.  Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects.

Authors:  P J Klasse; R Pipkorn; J Blomberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-07       Impact factor: 11.205

8.  Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry.

Authors:  A Takeda; C U Tuazon; F A Ennis
Journal:  Science       Date:  1988-10-28       Impact factor: 47.728

9.  Lysis of oncornaviruses by human serum. Isolation of the viral complement (C1) receptor and identification as p15E.

Authors:  R M Bartholomew; A F Esser; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1978-03-01       Impact factor: 14.307

10.  Epstein-Barr virus regulates activation and processing of the third component of complement.

Authors:  C Mold; B M Bradt; G R Nemerow; N R Cooper
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  59 in total

1.  Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis.

Authors:  W S Hlavacek; C Wofsy; A S Perelson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  The immunosuppressive domain of the transmembrane envelope protein gp41 of HIV-1 binds to human monocytes and B cells.

Authors:  Michael Mühle; Tobias Kroniger; Kerstin Hoffmann; Joachim Denner
Journal:  Immunol Res       Date:  2016-06       Impact factor: 2.829

Review 3.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

Review 4.  Role of complement and Fc receptors in the pathogenesis of HIV-1 infection.

Authors:  D C Montefiori
Journal:  Springer Semin Immunopathol       Date:  1997

5.  Activation of the classical complement pathway by Bacillus anthracis is the primary mechanism for spore phagocytosis and involves the spore surface protein BclA.

Authors:  Chunfang Gu; Sarah A Jenkins; Qiong Xue; Yi Xu
Journal:  J Immunol       Date:  2012-03-21       Impact factor: 5.422

6.  CR1 (CD35) and CR3 (CD11b/CD18) mediate infection of human monocytes and monocytic cell lines with complement-opsonized HIV independently of CD4.

Authors:  N Thieblemont; N Haeffner-Cavaillon; A Ledur; J L'Age-Stehr; H W Ziegler-Heitbrock; M D Kazatchkine
Journal:  Clin Exp Immunol       Date:  1993-04       Impact factor: 4.330

7.  Interaction of complement and specific antibodies with the external glycoprotein 120 of HIV-1.

Authors:  Z Prohászka; T Hidvégi; E Ujhelyi; H Stoiber; M P Dierich; C Süsal; G Füst
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

8.  Antibody-dependent complement-mediated cytotoxicity in sera from patients with HIV-1 infection is controlled by CD55 and CD59.

Authors:  J Schmitz; J P Zimmer; B Kluxen; S Aries; M Bögel; I Gigli; H Schmitz
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

9.  A high-affinity inhibitor of human CD59 enhances complement-mediated virolysis of HIV-1: implications for treatment of HIV-1/AIDS.

Authors:  Weiguo Hu; Qigui Yu; Ningjie Hu; Daniel Byrd; Tohti Amet; Cecilia Shikuma; Bruce Shiramizu; Jose A Halperin; Xuebin Qin
Journal:  J Immunol       Date:  2009-12-02       Impact factor: 5.422

10.  HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway.

Authors:  Hugues Fausther-Bovendo; Vincent Vieillard; Sandrine Sagan; Georges Bismuth; Patrice Debré
Journal:  PLoS Pathog       Date:  2010-07-01       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.